CTOs on the Move

Gate Pharmaceuticals

www.biocraft.com

 
Gate Pharmaceuticals is a North Wales, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.biocraft.com
  • 1090 Horsham Rd
    North Wales, PA USA 19454
  • Phone: 215.591.3000

Executives

Name Title Contact Details

Similar Companies

Wallace Pharmaceuticals

Wallace Pharmaceuticals is a Somerset, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Bausch Health Companies

Bausch Health Companies Inc. is a multinational specialty pharmaceutical company based in Laval, Canada.

Albireo Pharma

Albireo Pharma is a clinical-stage biopharmaceutical company focused through its operating subsidiary on the development of novel bile acid modulators to treat orphan pediatric liver diseases, and other liver and gastrointestinal diseases and disorders. Albireo`s lead product candidate, A4250, is directed to treat rare pediatric cholestatic liver diseases and is in Phase 3 development in its initial target indication, progressive familial intrahepatic cholestasis. Albireo`s clinical pipeline also includes two Phase 2 product candidates. Albireo`s elobixibat, approved in Japan for the treatment of chronic constipation, is the first ileal bile acid transporter (IBAT) inhibitor approved anywhere in the world. Albireo was spun out from AstraZeneca in 2008. Albireo Pharma is located in Boston, Massachusetts, and its key operating subsidiary is located in Gothenburg, Sweden.

Fluid Air

Fluid Air is a Aurora, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Nektar

Nektar Therapeutics is a research-based development stage biopharmaceutical company that discovers and develops innovative medicines in areas of high unmet medical need. Our R&D pipeline of new investigational drugs includes treatments for cancer, auto-immune disease and chronic pain. We leverage Nektar`s proprietary and proven chemistry platform in the discovery and design of our new drug candidates.